| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 2864894 | The American Journal of the Medical Sciences | 2006 | 4 Pages | 
Abstract
												Bucillamine, a disease-modifying antirheumatic drug, can have adverse effects, including lung injury. Development of interstitial pneumonia during treatment for patients with rheumatoid arthritis (RA) can pose a difficult differential diagnosis between a direct manifestation of RA and a drug effect. Our review of previous reports suggested bucillamine-induced interstitial pneumonia in the patient described here, visualized by chest radiography and computed tomography based on patchy ground-glass opacities in a peribronchial or peripheral distribution, suggesting the appearance of bronchiolitis obliterans organizing pneumonia (BOOP). As is typical for BOOP, steroid responsiveness may have contributed to recovery.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Cardiology and Cardiovascular Medicine
												
											Authors
												Takashi MD, Atsushi MD, Daisuke MD, Chuwa MD, 
											